Skip to main content

Groenhuysen Wilhelmus CM's Form 4 filing

NovoCure Ltd (NVCR) · filed Mar 2, 2023

Accession no.
0001645113-23-000025
Filed
Mar 2, 2023
Trade date
Feb 28-Mar 1, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $165.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Groenhuysen Wilhelmus CMCIK 0001264783Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 28, 2023Ordinary SharesAGrant or awardAcquired+21,653$0.00$0186,779Direct
Mar 1, 2023Ordinary SharesSSaleDisposed−2,164$76.36−$165,243.04184,615Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 28, 2023Ordinary SharesAGrant or awardAcquired+36,013$76.97+$2,771,920.6136,013Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)